1
|
Abdulameer NJ, Acharya U, Adare A, Aidala C, Ajitanand NN, Akiba Y, Akimoto R, Alfred M, Apadula N, Aramaki Y, Asano H, Atomssa ET, Awes TC, Azmoun B, Babintsev V, Bai M, Bandara NS, Bannier B, Barish KN, Bathe S, Bazilevsky A, Beaumier M, Beckman S, Belmont R, Berdnikov A, Berdnikov Y, Bichon L, Black D, Blankenship B, Bok JS, Borisov V, Boyle K, Brooks ML, Bryslawskyj J, Buesching H, Bumazhnov V, Campbell S, Canoa Roman V, Chen CH, Chiu M, Chi CY, Choi IJ, Choi JB, Chujo T, Citron Z, Connors M, Corliss R, Corrales Morales Y, Csanád M, Csörgő T, Datta A, Daugherity MS, David G, Dean CT, DeBlasio K, Dehmelt K, Denisov A, Deshpande A, Desmond EJ, Ding L, Dion A, Doomra V, Do JH, Drees A, Drees KA, Durham JM, Durum A, En'yo H, Enokizono A, Esha R, Fadem B, Fan W, Feege N, Fields DE, Finger M, Finger M, Firak D, Fitzgerald D, Fokin SL, Frantz JE, Franz A, Frawley AD, Gallus P, Gal C, Garg P, Ge H, Giles M, Giordano F, Glenn A, Goto Y, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Guragain H, Gu Y, Hachiya T, Haggerty JS, Hahn KI, Hamagaki H, Hanks J, Han SY, Harvey M, Hasegawa S, Hemmick TK, He X, Hill JC, Hodges A, Hollis RS, Homma K, Hong B, Hoshino T, Huang J, Ikeda Y, Imai K, Imazu Y, Inaba M, Iordanova A, Isenhower D, Ivanishchev D, Jacak BV, Jeon SJ, Jezghani M, Jiang X, Ji Z, Johnson BM, Joo E, Joo KS, Jouan D, Jumper DS, Kang JH, Kang JS, Kawall D, Kazantsev AV, Key JA, Khachatryan V, Khanzadeev A, Khatiwada A, Kihara K, Kim C, Kim DH, Kim DJ, Kim EJ, Kim HJ, Kim M, Kim T, Kim YK, Kincses D, Kingan A, Kistenev E, Klatsky J, Kleinjan D, Kline P, Koblesky T, Kofarago M, Koster J, Kotov D, Kovacs L, Kurgyis B, Kurita K, Kurosawa M, Kwon Y, Lajoie JG, Larionova D, Lebedev A, Lee KB, Lee SH, Leitch MJ, Leitgab M, Lewis NA, Lim SH, Liu MX, Li X, Loomis DA, Lynch D, Lökös S, Majoros T, Makdisi YI, Makek M, Manion A, Manko VI, Mannel E, McCumber M, McGaughey PL, McGlinchey D, McKinney C, Meles A, Mendoza M, Meredith B, Miake Y, Mignerey AC, Miller AJ, Milov A, Mishra DK, Mitchell JT, Mitrankova M, Mitrankov I, Miyasaka S, Mizuno S, Mondal MM, Montuenga P, Moon T, Morrison DP, Moukhanova TV, Muhammad A, Mulilo B, Murakami T, Murata J, Mwai A, Nagamiya S, Nagle JL, Nagy MI, Nakagawa I, Nakagomi H, Nakano K, Nattrass C, Nelson S, Netrakanti PK, Nihashi M, Niida T, Nouicer R, Novitzky N, Nukazuka G, Nyanin AS, O'Brien E, Ogilvie CA, Oh J, Orjuela Koop JD, Orosz M, Osborn JD, Oskarsson A, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park JS, Park S, Patel L, Patel M, Pate SF, Peng JC, Peng W, Perepelitsa DV, Perera GDN, Peressounko DY, PerezLara CE, Perry J, Petti R, Pinkenburg C, Pinson R, Pisani RP, Potekhin M, Pun A, Purschke ML, Radzevich PV, Rak J, Ramasubramanian N, Ravinovich I, Read KF, Reynolds D, Riabov V, Riabov Y, Richford D, Riveli N, Roach D, Rolnick SD, Rosati M, Rowan Z, Rubin JG, Runchey J, Saito N, Sakaguchi T, Sako H, Samsonov V, Sarsour M, Sato S, Sawada S, Schaefer B, Schmoll BK, Sedgwick K, Seele J, Seidl R, Sen A, Seto R, Sett P, Sexton A, Sharma D, Shein I, Shibata M, Shibata TA, Shigaki K, Shimomura M, Shi Z, Shukla P, Sickles A, Silva CL, Silvermyr D, Singh BK, Singh CP, Singh V, Slunečka M, Smith KL, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Stankus PW, Stepanov M, Stoll SP, Sugitate T, Sukhanov A, Sumita T, Sun J, Sun Z, Sziklai J, Takahama R, Takahara A, Taketani A, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Timilsina A, Todoroki T, Tomášek M, Torii H, Towell M, Towell R, Towell RS, Tserruya I, Ueda Y, Ujvari B, van Hecke HW, Vargyas M, Velkovska J, Virius M, Vrba V, Vznuzdaev E, Wang XR, Wang Z, Watanabe D, Watanabe Y, Watanabe YS, Wei F, Whitaker S, Wolin S, Wong CP, Woody CL, Wysocki M, Xia B, Xue L, Yalcin S, Yamaguchi YL, Yanovich A, Yoon I, Younus I, Yushmanov IE, Zajc WA, Zelenski A, Zou L. Measurement of Direct-Photon Cross Section and Double-Helicity Asymmetry at sqrt[s]=510 GeV in p[over →]+p[over →] Collisions. PHYSICAL REVIEW LETTERS 2023; 130:251901. [PMID: 37418716 DOI: 10.1103/physrevlett.130.251901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 11/04/2022] [Accepted: 04/28/2023] [Indexed: 07/09/2023]
Abstract
We present measurements of the cross section and double-helicity asymmetry A_{LL} of direct-photon production in p[over →]+p[over →] collisions at sqrt[s]=510 GeV. The measurements have been performed at midrapidity (|η|<0.25) with the PHENIX detector at the Relativistic Heavy Ion Collider. At relativistic energies, direct photons are dominantly produced from the initial quark-gluon hard scattering and do not interact via the strong force at leading order. Therefore, at sqrt[s]=510 GeV, where leading-order-effects dominate, these measurements provide clean and direct access to the gluon helicity in the polarized proton in the gluon-momentum-fraction range 0.02<x<0.08, with direct sensitivity to the sign of the gluon contribution.
Collapse
|
2
|
Oda H, Kihara K, Morimoto Y, Takeuchi S. Cell-Based Biohybrid Sensor Device for Chemical Source Direction Estimation. CYBORG AND BIONIC SYSTEMS 2021; 2021:8907148. [PMID: 36285129 PMCID: PMC9494699 DOI: 10.34133/2021/8907148] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Accepted: 12/31/2020] [Indexed: 02/03/2023] Open
Abstract
This paper describes a method to estimate the direction from which the signal molecule reaches the sensor by using living cells. In this context, biohybrid sensors that utilize a sophisticated sensing system of cells can potentially offer high levels of chemical-detection sensitivity and selectivity. However, biohybrid-sensor-based chemical-source-direction estimation has not received research attention because the cellular response to chemicals has not been examined in the context of directional information. In our approach, we fabricated a device that can limit the interface between the cell-laden hydrogel and the chemical solution of interest to enhance the time difference over which the chemical solution reaches the cells. Chemical detection by cells that express specific receptors is reflected as the fluorescence of the calcium indicator within the cells. Our device has eight chambers that each house 3D cell-laden collagen hydrogels facing circularly outward. The device also works as a cover to prevent chemicals from permeating the hydrogel from above. In our study, by observing the time course of the fluorescence emission of each chamber, we were able to successfully estimate the chemical-source direction within an error range of 7–13°. Our results suggest that a combination of microstructure devices embedded with living cells can be used to exploit cell functionalities to yield chemical-source directional information.
Collapse
|
3
|
Shimojima R, Otsuka H, Kihara K, Sakamoto T, Mitsumaru A, Watanabe K, Sakuma A, Yamada Y, Okayama S, Yano Y, Yokomizo H, Yoshimatsu K, Naritaka Y, Kato H. [Endoscopic Submucosal Dissection(ESD)as a "Loco-Regional Cancer Therapy" for Colorectal Tumors]. Gan To Kagaku Ryoho 2019; 46:321-323. [PMID: 30914547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
INTRODUCTION Endoscopic submucosal dissection(ESD)for colorectal tumors has been covered by the national health insurance system in Japan since April 2012, and is widely used. We analyzed colorectal ESD cases we performed. PATIENTS AND METHODS We investigated 515 patients with colorectal lesions(580 lesions)for whom ESD was performed between November 2005 and April 2017. Clinicopathological data, technical methods, complications, and outcomes were analyzed. RESULTS Most tumors were found in the transverse colon(134 lesions). The average diameter was about 26 mm. The largest lesion was 120 mm. The en bloc resection rate was high(96.2%). The average operative time was 51 minutes. Among complications, the number of delayed major bleeding cases was 7(1.2%). Minor perforations occurred in 3 cases(0.5%). The perforation could be closed with endoscopic clips. About 70% of the cases were adenomas, and the remainder were carcinomas. One patient with carcinoma in situ showed a mucosal recurrence 4 months later and received repeat endoscopic treatment. The cure rate was 99.8%. Among 29 deep submucosal invasion cases, additional colectomy was performed in 21; 3 patients had persistent carcinoma in the colonic wall and another patient had lymph node metastasis. CONCLUSIONS Colorectal ESD can be performed for all sites in the large intestine, and en bloc resection was possible for a large lesion. A good outcome was observed for "Loco-Regional Cancer Therapy" in early colorectal carcinoma.
Collapse
|
4
|
Izumi K, Saito K, Nakayama T, Fukuda S, Fukushima H, Uehara S, Koga F, Yonese J, Kageyama Y, Kihara K, Fujii Y. Contact with renal sinus is a significant risk factor for metastasis in pT1 clear cell renal cell carcinoma. ACTA ACUST UNITED AC 2017. [DOI: 10.1016/s1569-9056(17)30705-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
5
|
Adare A, Aidala C, Ajitanand N, Akiba Y, Akimoto R, Alfred M, Apadula N, Aramaki Y, Asano H, Atomssa E, Awes T, Azmoun B, Babintsev V, Bai M, Bandara N, Bannier B, Barish K, Bathe S, Bazilevsky A, Beaumier M, Beckman S, Belmont R, Berdnikov A, Berdnikov Y, Black D, Blau D, Bok J, Boyle K, Brooks M, Bryslawskyj J, Buesching H, Bumazhnov V, Campbell S, Chen CH, Chi C, Chiu M, Choi I, Choi J, Chujo T, Citron Z, Csanád M, Csörgő T, Danley T, Datta A, Daugherity M, David G, DeBlasio K, Dehmelt K, Denisov A, Deshpande A, Desmond E, Ding L, Dion A, Diss P, Do J, Drees A, Drees K, Durham J, Durum A, Enokizono A, En’yo H, Esumi S, Fadem B, Feege N, Fields D, Finger M, Finger M, Fokin S, Frantz J, Franz A, Frawley A, Gal C, Gallus P, Garg P, Ge H, Giordano F, Glenn A, Goto Y, Grau N, Greene S, Grosse Perdekamp M, Gu Y, Gunji T, Guragain H, Hachiya T, Haggerty J, Hahn K, Hamagaki H, Hamilton H, Han S, Hanks J, Hasegawa S, Haseler T, Hashimoto K, He X, Hemmick T, Hill J, Hollis R, Homma K, Hong B, Hoshino T, Hotvedt N, Huang J, Huang S, Ikeda Y, Imai K, Imazu Y, Inaba M, Iordanova A, Isenhower D, Ivanishchev D, Jacak B, Jeon S, Jezghani M, Jia J, Jiang X, Johnson B, Joo E, Joo K, Jouan D, Jumper D, Kanda S, Kang J, Kang J, Kawall D, Kazantsev A, Key J, Khachatryan V, Khanzadeev A, Kihara K, Kim C, Kim D, Kim D, Kim EJ, Kim G, Kim HJ, Kim M, Kim Y, Kimelman B, Kistenev E, Kitamura R, Klatsky J, Kleinjan D, Kline P, Koblesky T, Kofarago M, Komkov B, Koster J, Kotov D, Kurita K, Kurosawa M, Kwon Y, Lacey R, Lajoie J, Lebedev A, Lee K, Lee S, Lee S, Leitch M, Leitgab M, Li X, Lim S, Liu M, Lynch D, Makdisi Y, Makek M, Manion A, Manko V, Mannel E, McCumber M, McGaughey P, McGlinchey D, McKinney C, Meles A, Mendoza M, Meredith B, Miake Y, Mignerey A, Miller A, Milov A, Mishra D, Mitchell J, Miyasaka S, Mizuno S, Mohanty A, Montuenga P, Moon T, Morrison D, Moukhanova T, Murakami T, Murata J, Mwai A, Nagamiya S, Nagashima K, Nagle J, Nagy M, Nakagawa I, Nakagomi H, Nakano K, Nattrass C, Netrakanti P, Nihashi M, Niida T, Nishimura S, Nouicer R, Novák T, Novitzky N, Nyanin A, O’Brien E, Ogilvie C, Orjuela Koop J, Osborn J, Oskarsson A, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park J, Park S, Pate S, Patel L, Patel M, Peng JC, Perepelitsa D, Perera G, Peressounko D, Perry J, Petti R, Pinkenburg C, Pinson R, Pisani R, Purschke M, Rak J, Ramson B, Ravinovich I, Read K, Reynolds D, Riabov V, Riabov Y, Rinn T, Riveli N, Roach D, Rolnick S, Rosati M, Rowan Z, Rubin J, Sahlmueller B, Saito N, Sakaguchi T, Sako H, Samsonov V, Sarsour M, Sato S, Sawada S, Schaefer B, Schmoll B, Sedgwick K, Seele J, Seidl R, Sen A, Seto R, Sett P, Sexton A, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shukla P, Sickles A, Silva C, Silvermyr D, Singh B, Singh C, Singh V, Slunečka M, Snowball M, Soltz R, Sondheim W, Sorensen S, Sourikova I, Stankus P, Stepanov M, Stoll S, Sugitate T, Sukhanov A, Sumita T, Sun J, Sziklai J, Takahara A, Taketani A, Tanida K, Tannenbaum M, Tarafdar S, Taranenko A, Tieulent R, Timilsina A, Todoroki T, Tomášek M, Torii H, Towell C, Towell M, Towell R, Towell R, Tserruya I, van Hecke H, Vargyas M, Velkovska J, Virius M, Vrba V, Vznuzdaev E, Wang X, Watanabe D, Watanabe Y, Watanabe Y, Wei F, Whitaker S, White A, Wolin S, Woody C, Wysocki M, Xia B, Xue L, Yalcin S, Yamaguchi Y, Yanovich A, Yoo J, Yoon I, Younus I, Yu H, Yushmanov I, Zajc W, Zelenski A, Zhou S, Zou L. Measurements of double-helicity asymmetries in inclusive
J/ψ
production in longitudinally polarized
p+p
collisions at
s=510
GeV. Int J Clin Exp Med 2016. [DOI: 10.1103/physrevd.94.112008] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
6
|
Fujisawa T, Iwata H, Sakai T, Nakamura R, Hasegawa Y, Ohtani S, Kashiwaba M, Taira N, Toyama T, Masuda N, Yamamoto Y, Kihara K, Shimozuma K, Ohashi Y, Mukai H. Abstract P4-11-02: Endocrine-related symptoms during neoadjuvant endocrine therapy for breast cancer: Agreement between patient and physician reporting in a prospective clinical trial. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-11-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: There is a high risk of under-reporting subjective toxicities by physicians, even when collected prospectively in clinical trials. It has been recommended to include patient reported measures regarding symptoms in prospective clinical comparative effectiveness trials. However, there have been few reports of agreement in endocrine related symptoms between patient and physician reporting.
Patients and Method: The National Surgical Adjuvant Study of Breast Cancer 06 (N-SAS BC 06) is a multicenter, randomized clinical trial of postmenopausal, hormone receptor-positive breast cancer patients, with a two-stage (preoperative and postoperative) enrollment, and intervention. The primary aim was to evaluate the need for adjuvant chemotherapy in the treatment of postmenopausal breast cancer patients who responded to neoadjuvant treatment with Letrozole (LET) for 24-28 weeks. After surgery, responders were randomized into two arms receiving either chemotherapy plus LET, or LET alone. The primary endpoint was disease-free survival, and the secondary endpoints included adverse events, quality of life and health economic evaluation. This study enrolled 497 subjects from the N-SAS BC 06 who were evaluated by Patient Reported Outcomes (PROs). The concordance rate between Clinician Reported Outcomes (CROs) and PROs in their endocrine symptoms during neoadjuvant endocrine therapy was examined. Symptoms were collected prospectively by physicians using the Common Toxicity Criteria for Adverse Events at enrollment, i.e., baseline, and 4 and 16 weeks after starting neoadjuvant LET. Patients also completed the FACT-G (General), B (Breast), ES (Endocrine Symptoms), and HADS. The endocrine symptoms according to the PROs, included nausea, hot flushes, cold sweats, headaches, and HADS-Depression score. In FACT, "Not at all" was used to express the absence of the symptoms, and "A little bit", "Some-what", "Quite a bit", and "Very much" were used to express the presence of symptoms. The HADS-Depression score threshold was 10/11. According to the CROs, grade 0 was defined as the absence of symptoms and grade 1 or more was defined as the presence of symptoms. Cohen's kappa was used to determine the concordance between CROs and PROs. The sensitivity of CROs was also calculated.
Results: The calculated point estimates of Cohen's kappa at Weeks 4 and 16 after starting neoadjuvant LET were 0.12 and 0.01 for nausea, 0.16 and 0.18 for hot flushes, 0.12 and 0.09 for cold sweats, 0.03 and 0.02 for headaches, and 0.11 and 0.11 for dysthymia/depression, respectively; the concordance was quite low. The sensitivity of CROs at Weeks 4 and 16 after starting neoadjuvant LET was 0.07 and 0.03 for nausea, 0.16 and 0.17 for hot flushes, 0.1 and 0.08 for cold sweats, 0.03 and 0.03 for headaches, and 0.11 and 0.1 for dysthymia/depression, respectively; the sensitivity was quite low.
Conclusion: This study showed that there were big differences between CROs and PROs in endocrine symptoms associated with endocrine therapy for breast cancer and that physicians could not obtain sufficient information on the endocrine symptoms. It is recommended that PROs be used to evaluate adverse events caused by endocrine therapy.
Citation Format: Fujisawa T, Iwata H, Sakai T, Nakamura R, Hasegawa Y, Ohtani S, Kashiwaba M, Taira N, Toyama T, Masuda N, Yamamoto Y, Kihara K, Shimozuma K, Ohashi Y, Mukai H. Endocrine-related symptoms during neoadjuvant endocrine therapy for breast cancer: Agreement between patient and physician reporting in a prospective clinical trial. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-11-02.
Collapse
|
7
|
Adare A, Aidala C, Ajitanand N, Akiba Y, Akimoto R, Alexander J, Alfred M, Aoki K, Apadula N, Aramaki Y, Asano H, Atomssa E, Awes T, Azmoun B, Babintsev V, Bai M, Bai X, Bandara N, Bannier B, Barish K, Bathe S, Baublis V, Baumann C, Baumgart S, Bazilevsky A, Beaumier M, Beckman S, Belmont R, Berdnikov A, Berdnikov Y, Black D, Blau D, Bok J, Boyle K, Brooks M, Bryslawskyj J, Buesching H, Bumazhnov V, Butsyk S, Campbell S, Chen CH, Chi C, Chiu M, Choi I, Choi J, Choi S, Christiansen P, Chujo T, Cianciolo V, Citron Z, Cole B, Cronin N, Crossette N, Csanád M, Csörgő T, Danley T, Datta A, Daugherity M, David G, DeBlasio K, Dehmelt K, Denisov A, Deshpande A, Desmond E, Ding L, Dion A, Diss P, Do J, D’Orazio L, Drapier O, Drees A, Drees K, Durham J, Durum A, Engelmore T, Enokizono A, En’yo H, Esumi S, Eyser K, Fadem B, Feege N, Fields D, Finger M, Finger M, Fleuret F, Fokin S, Frantz J, Franz A, Frawley A, Fukao Y, Fusayasu T, Gainey K, Gal C, Gallus P, Garg P, Garishvili A, Garishvili I, Ge H, Giordano F, Glenn A, Gong X, Gonin M, Goto Y, Granier de Cassagnac R, Grau N, Greene S, Grosse Perdekamp M, Gu Y, Gunji T, Guragain H, Hachiya T, Haggerty J, Hahn K, Hamagaki H, Hamilton H, Han S, Hanks J, Hasegawa S, Haseler T, Hashimoto K, Hayano R, He X, Hemmick T, Hester T, Hill J, Hollis R, Homma K, Hong B, Hoshino T, Hotvedt N, Huang J, Huang S, Ichihara T, Ikeda Y, Imai K, Imazu Y, Inaba M, Iordanova A, Isenhower D, Isinhue A, Ivanishchev D, Jacak B, Jeon S, Jezghani M, Jia J, Jiang X, Johnson B, Joo E, Joo K, Jouan D, Jumper D, Kamin J, Kanda S, Kang B, Kang J, Kang J, Kapustinsky J, Kawall D, Kazantsev A, Key J, Khachatryan V, Khandai P, Khanzadeev A, Kihara K, Kijima K, Kim C, Kim D, Kim D, Kim EJ, Kim G, Kim HJ, Kim M, Kim YJ, Kim Y, Kimelman B, Kistenev E, Kitamura R, Klatsky J, Kleinjan D, Kline P, Koblesky T, Kofarago M, Komkov B, Koster J, Kotchetkov D, Kotov D, Krizek F, Kurita K, Kurosawa M, Kwon Y, Lacey R, Lai Y, Lajoie J, Lebedev A, Lee D, Lee G, Lee J, Lee K, Lee K, Lee S, Lee S, Leitch M, Leitgab M, Lewis B, Li X, Lim S, Liu M, Lynch D, Maguire C, Makdisi Y, Makek M, Manion A, Manko V, Mannel E, Maruyama T, McCumber M, McGaughey P, McGlinchey D, McKinney C, Meles A, Mendoza M, Meredith B, Miake Y, Mibe T, Mignerey A, Miller A, Milov A, Mishra D, Mitchell J, Miyasaka S, Mizuno S, Mohanty A, Mohapatra S, Montuenga P, Moon T, Morrison D, Moskowitz M, Moukhanova T, Murakami T, Murata J, Mwai A, Nagae T, Nagamiya S, Nagashima K, Nagle J, Nagy M, Nakagawa I, Nakagomi H, Nakamiya Y, Nakamura K, Nakamura T, Nakano K, Nattrass C, Netrakanti P, Nihashi M, Niida T, Nishimura S, Nouicer R, Novák T, Novitzky N, Nyanin A, O’Brien E, Ogilvie C, Oide H, Okada K, Orjuela Koop J, Osborn J, Oskarsson A, Ozaki H, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park I, Park J, Park S, Park S, Pate S, Patel L, Patel M, Peng JC, Perepelitsa D, Perera G, Peressounko D, Perry J, Petti R, Pinkenburg C, Pinson R, Pisani R, Purschke M, Qu H, Rak J, Ramson B, Ravinovich I, Read K, Reynolds D, Riabov V, Riabov Y, Richardson E, Rinn T, Riveli N, Roach D, Rolnick S, Rosati M, Rowan Z, Rubin J, Ryu M, Sahlmueller B, Saito N, Sakaguchi T, Sako H, Samsonov V, Sarsour M, Sato S, Sawada S, Schaefer B, Schmoll B, Sedgwick K, Seele J, Seidl R, Sekiguchi Y, Sen A, Seto R, Sett P, Sexton A, Sharma D, Shaver A, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva C, Silvermyr D, Singh B, Singh C, Singh V, Skolnik M, Slunečka M, Snowball M, Solano S, Soltz R, Sondheim W, Sorensen S, Sourikova I, Stankus P, Steinberg P, Stenlund E, Stepanov M, Ster A, Stoll S, Stone M, Sugitate T, Sukhanov A, Sumita T, Sun J, Sziklai J, Takahara A, Taketani A, Tanaka Y, Tanida K, Tannenbaum M, Tarafdar S, Taranenko A, Tennant E, Tieulent R, Timilsina A, Todoroki T, Tomášek M, Torii H, Towell C, Towell M, Towell R, Towell R, Tserruya I, van Hecke H, Vargyas M, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Virius M, Vrba V, Vznuzdaev E, Wang X, Watanabe D, Watanabe K, Watanabe Y, Watanabe Y, Wei F, Whitaker S, White A, Wolin S, Woody C, Wysocki M, Xia B, Xue L, Yalcin S, Yamaguchi Y, Yanovich A, Yokkaichi S, Yoo J, Yoon I, You Z, Younus I, Yu H, Yushmanov I, Zajc W, Zelenski A, Zhou S, Zou L. Inclusive cross section and double-helicity asymmetry forπ0production at midrapidity inp+pcollisions ats=510 GeV. Int J Clin Exp Med 2016. [DOI: 10.1103/physrevd.93.011501] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
8
|
Mogi K, Shirataki C, Kihara K, Kuwahara H, Hongoh Y, Yamamoto T. Trapping and isolation of single prokaryotic cells in a micro-chamber array using dielectrophoresis. RSC Adv 2016. [DOI: 10.1039/c6ra21229h] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
The vast majority of prokaryotic species are difficult or impossible to culture in laboratories, which makes it difficult to study these organisms using conventional biochemical techniques.
Collapse
|
9
|
Kihara K. Addenda and corrigendum for "On the split-atom model for hexagonal tridymite". Z KRIST-CRYST MATER 2015. [DOI: 10.1524/zkri.1981.157.14.93] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
10
|
Kihara K, Takeuchi T, Yoshimoto S, Kondo H, Kawahara J. The locus coeruleus-noradrenaline system facilitates attentional processing of action-triggered visual stimuli. J Vis 2014. [DOI: 10.1167/14.10.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
11
|
Uchida Y, Yoshida S, Kobayashi S, Koga F, Ishioka J, Satoh S, Ishii C, Tanaka H, Matsuoka Y, Numao N, Saito K, Masuda H, Fujii Y, Kihara K. Diffusion-weighted MRI as a potential imaging biomarker reflecting the metastatic potential of upper urinary tract cancer. Br J Radiol 2014; 87:20130791. [PMID: 25074719 DOI: 10.1259/bjr.20130791] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
OBJECTIVE To evaluate the role of diffusion-weighted MRI (DW-MRI) as an imaging biomarker for upper urinary tract cancer (UUTC) that has already metastasized or will metastasize soon. METHODS 61 patients clinically diagnosed with UUTC were prospectively enrolled in this study. All the patients underwent MRI, including DW-MRI, prior to any interventions. Correlations between apparent diffusion coefficient (ADC) and other clinicopathological variables, including metastasis-free survival, were analysed. RESULTS Median follow-up period was 938 days. Of the 61 patients, 12 had any metastases at the initial diagnosis. 11 patients developed metastases during the follow-up period. These 23 patients were categorized as "Metastatic". Of the remaining 38 patients, 35 with a follow-up period longer than 400 days were categorized as "Localized". ADC was significantly lower in the Metastatic category than in the Localized (p = 0.0002) category. Multivariate analysis of pre-operative variables identified ADC (cut-off value, 1.08 × 10(-3) mm(2) s(-1)) and clinical T stage based on T2 weighted MRI as an independent predictive factor of metastatic UUTC. 46 patients without any metastases during the initial diagnosis were stratified into a high-risk group (16 patients with low ADC and clinical T3-4) and a low-risk group (30 patients with high ADC or clinical Ta-2). The 3-year metastasis-free survivals were 45% and 93%, respectively. CONCLUSION In the current study, UUTC with lower ADC value is more likely to have metastatic potential. Incorporating ADC with clinical T stage helps to differentiate metastatic UUTC at the initial diagnosis. ADVANCES IN KNOWLEDGE DW-MRI is a potential imaging biomarker reflecting metastatic propensity of UUTC.
Collapse
|
12
|
Kihara K, Fujii Y, Saito K, Masuda H, Koga F, Numao N, Ishioka J, Matsuoka Y. V28 New 3-dimensional head-mounted display system (RoboSurgeon System) applied to gasless, two-port access total nephroureterectomy. ACTA ACUST UNITED AC 2014. [DOI: 10.1016/s1569-9056(14)61157-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Fukushima H, Masuda H, Yokoyama M, Tatokoro M, Yoshida S, Ishioka J, Matsuoka Y, Numao N, Koga F, Saito K, Fujii Y, Kihara K. Diabetes Mellitus with Obesity is a Predictor of Recurrence in Patients with Non-metastatic Renal Cell Carcinoma. Jpn J Clin Oncol 2013; 43:740-6. [DOI: 10.1093/jjco/hyt070] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Kihara K, Takeshita H, Masuda H, Koga F, Saito K, Matsuoka Y, Numao N, Fujii Y. 950 Novel three-dimensional head-mounted display system (RoboSurgeon System) – application to the initial 60 cases of gasless single-port access urologic surgeries. ACTA ACUST UNITED AC 2013. [DOI: 10.1016/s1569-9056(13)61429-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
15
|
Kihara K, Fujii Y, Masuda H, Saito K, Koga F, Numao N, Matsuoka Y. V61 New 3-dimensional head-mounted display system (RoboSurgeon system) applied to gasless, single-port access adrenalectomy. ACTA ACUST UNITED AC 2013. [DOI: 10.1016/s1569-9056(13)61644-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
16
|
Okugawa S, Mekata T, Inada M, Kihara K, Shiki A, Kannabiran K, Kono T, Sakai M, Yoshida T, Itami T, Sudhakaran R. The SOCS and STAT from JAK/STAT signaling pathway of kuruma shrimp Marsupenaeus japonicus: molecular cloning, characterization and expression analysis. Mol Cell Probes 2012; 27:6-14. [PMID: 22921512 DOI: 10.1016/j.mcp.2012.08.003] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2012] [Revised: 07/12/2012] [Accepted: 08/08/2012] [Indexed: 01/22/2023]
Abstract
Signal transducer and activators of transcription (STAT) gene, suppressors of cytokine signaling (SOCS) has been isolated from kuruma shrimp, Marsupenaeus japonicus and characterized. The kuruma shrimp STAT (MjSTAT) cDNA was composed of 2901 bp consisting of 801 amino acid residues which includes a protein interaction domain, all alpha domain, DNA binding domain and SH2 domain. Homology analysis of MjSTAT showed 94.1% and 34.0% identities with Penaeus monodon STAT (PmSTAT) and Drosophila melanogaster STAT92E (DmSTAT), respectively. The kuruma shrimp SOCS (MjSOCS) cDNA was composed of 1675 bp consisting of 342 amino acid residues including a SH2 domain and C-terminal SOCS domain. Homology analysis of MjSOCS showed 52.6% and 21.3% identities with Chinese mitten crab (Eriocheir sinensis) SOCS2 and fruit fly (D. melanogaster) SOCS44A, respectively. The MjSTAT and MjSOCS genes are constitutively expressed in the muscle, stomach, brain and gill of kuruma shrimp. In lymphoid organ cells, an enhanced expression of both MjSTAT and MjSOCS genes are observed following stimulation with peptidoglycan and polycytidylic acid. These observations suggest that MjSTAT and MjSOCS might play a major role in the innate immune defense of kuruma shrimp. The discovery of JAK/STAT signaling pathway in shrimp will allow a complete and concrete understanding of shrimp cytokine signaling.
Collapse
|
17
|
Yamamoto M, Orihashi K, Nishimori H, Wariishi S, Fukutomi T, Kondo N, Kihara K, Sato T, Sasaguri S. Indocyanine Green Angiography for Intra-operative Assessment in Vascular Surgery. Eur J Vasc Endovasc Surg 2012; 43:426-32. [DOI: 10.1016/j.ejvs.2011.12.030] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2011] [Accepted: 12/28/2011] [Indexed: 10/14/2022]
|
18
|
Kihara K, Koga F, Masuda H, Saito K, Tatokoro M, Yokoyama M, Matsuoka Y, Numao N, Kawakami S, Fujii Y. 143 Feasibility of gasless single-port clampless partial nephrectomy for peripheral renal tumor: An experience of 118 consecutive cases. ACTA ACUST UNITED AC 2012. [DOI: 10.1016/s1569-9056(12)60142-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
19
|
Kihara K, Kawahara J. Voluntary production of visual items modulates transient attention twice. J Vis 2011. [DOI: 10.1167/11.11.121] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
20
|
Kitahara S, Nakayama T, Yano M, Kihara K. UP-02.209 Plasma D-dimer Levels in Prostate Cancer Patients Treated with Androgen Suppression Therapy. Urology 2011. [DOI: 10.1016/j.urology.2011.07.1027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
21
|
Sakura M, Kawakami S, Ishioka J, Fujii Y, Numao N, Saito K, Koga F, Masuda H, Fukui I, Kihara K. A novel repeat biopsy nomogram based on three-dimensional extended biopsy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
111 Background: There is no perfect cohort in which nomograms are developed because no biopsy method can detect all cancers. To minimize this inherent verification bias, having a cohort with fewer false negative cases is advantageous. Based on a cohort examined with three-dimensional (3D) extended biopsy protocol, we developed a novel nomogram for diagnosis of prostate cancer on repeat biopsy. Methods: Of 4,074 consecutive male patients undergoing prostate biopsy at our institutions between 2000 and 2009, 775 men with at least one previous negative biopsy underwent repeat biopsy with 3D protocol. Men with previous atypical glands or atypical small acinar proliferation and/or without available prostate-specific antigen (PSA) kinetics information were excluded. The remaining 515 men constituted the study cohort. We developed a logistic regression-based nomogram with 70% of the cohort selected randomly; we validated it with the remaining 30%. Predictive accuracy and performance characteristics were assessed using the area under the receiver operating characteristic curve (AUC) and calibration plots, respectively. The threshold probability was evaluated with decision curve analysis. Results: We developed a novel repeat biopsy nomogram incorporating age, free to total PSA ratio, prostate volume, history of previous extended biopsy, and PSA doubling time. Validation confirmed predictive accuracy with an AUC value of 0.791. Calibration plots showed good agreement. The decision curve of the nomogram was superior to the decision curve of biopsying all men in a range of threshold probability over 0.15. At the threshold of 0.2, the number of unnecessary biopsies could be reduced by 10 per 100, without missing PCa. Conclusions: We developed a novel repeat biopsy nomogram based on a cohort examined with 3D extended biopsy. This repeat biopsy nomogram is clinically beneficial, saving a substantial number of unnecessary biopsies. No significant financial relationships to disclose.
Collapse
|
22
|
Masuda H, Kawakami S, Sakura M, Fujii Y, Koga F, Saito K, Numao N, Yoshida S, Komai Y, Okada Y, Ito M, Yonese J, Fukui I, Kihara K. 12 PERFORMANCE OF FREE PSA BETTER THAN TOTAL PSA FOR ESTIMATION OF PROSTATE VOLUME IN ELDERLY MEN WITHOUT PROSTATE CANCER. ACTA ACUST UNITED AC 2011. [DOI: 10.1016/s1569-9056(11)60017-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
23
|
Fujii Y, Yoshida S, Yokoyama M, Iimura Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K. Maintenance of the suppressed level of serum testosterone by administration of three-monthly formulations of luteinizing hormone-releasing hormone agonists at six-month intervals in Japanese patients with prostate cancer: A prospective study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
159 Background: Treatment with an LH-RH agonist is a standard alternative to surgical castration for prostate cancer patients. The serum testosterone level is kept at castrate levels continuously during LH-RH agonist therapy in almost all patients (Fujii Y, BJU Int 2008). LH- RH agonists, however, are more expensive than surgical castration, with drugs costing between US $300 and $500 per month in Japan. Recent studies suggest that 3-monthly formulations of LH-RH agonists suppress the serum testosterone levels far longer than the 3-month dosing interval. Methods: A total of 43 Japanese patients with prostate cancer who were treated with 3-monthly LH-RH agonists (23 with 11.25mg leuprolide, and 20 with 10.8 mg goserelin) for one year or longer and whose testosterone levels were kept at castrate level (defined as < 50 ng/dL) were entered into this prospective, longitudinal study. After entry, the 43 men received the same 3-monthly LH-RH agonists at 6-month intervals, and had serum LH and testosterone tests performed at 3-month intervals. Bicalutamide was combined with the LH-RH agonists in 12 of the patients. Results: At entry, median patient age was 74 years (range 59 to 89), median duration of LH-RH agonists treatment was 26 months (12 to 125), and median LH and testosterone levels were <10 ng/dL (<10 to 60) and 5 ng/dL (<5 to 18), respectively. The 43 patients received a total of 162 administrations (median 5, range 1 to 6) of the LH-RH agonists at 6-month intervals, and had a total 335 hormonal tests (median 10, range 2 to12) performed during the median followup period of 30 months. Serum LH and testosterone levels were kept suppressed during the treatment. Of the 43 patients, two had serum testosterone just above the castrate level (54 and 56 ng/dL) once each among their 12 and 8 hormonal assays, respectively. Conclusions: Administration of 3-monthly LH-RH agonists, either leuprolide or goserelin, at 6-month intervals could maintain the castrate level of serum testosterone at least in Japanese prostate cancer patients who have received LH-RH agonists treatment for one year or longer. No significant financial relationships to disclose.
Collapse
|
24
|
Iimura Y, Saito K, Fujii Y, Ishioka J, Iwai A, Numao N, Okada Y, Koga F, Masuda H, Kihara K. Use of C-reactive protein to predict perinephric or renal sinus fat invasion in patients with clinical T1N0M0 renal cell carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
385 Background: Indication of nephron sparing surgery (NSS) for renal cell carcinoma (RCC) has been extending, as NSS can be considered for not only cT1a but also cT1b tumors. However, some cT1 diseases have pathological perinephric or renal sinus fat invasion. It is useful to know the probability of the presence of fat invasion before surgery, but diagnostic ability of imaging studies such as CT for predicting pT3a disease is limited. Therefore, estimation of the risk for pT3a disease in cT1 RCC patients could be helpful. C-reactive protein (CRP) has been shown to be a strong prognostic factor in RCC patients, reflecting tumor aggressiveness. We evaluated the predictive ability of preoperative CRP for pT3a disease in cT1N0M0 RCC patients. Methods: Of consecutive 386 patients treated with radical nephrectomy for cT1a-bN0M0 RCC, 82 were excluded due to hemodialysis, inflammatory disease, bilateral synchronous renal tumors, synchronous other malignant disease or loss of each data. The remaining 304 patients constituted the current study cohort. Cut off point of CRP was 3 mg/L. Associations were analyzed between pT3a and preoperative factors including age, sex, BMI, laterality, tumor size, CRP, hemoglobin, platelet, LDH, ALP, calcium and albumin. We developed a multivariate model for predicting pT3a disease in cT1 RCC. Results: Of the 304 patients, 28 (9%) had pT3a disease. Of 43 patients with elevated CRP level, 10 (23%) had pT3a disease. In contrast, of the remaining 261 patients with non-elevated CRP level, 18 (7%) had (p=0.002). Univariate and then multivariate analyses identified age (p=0.021), tumor size (p=0.007), and CRP (p=0.024) as independent and significant predictors for pT3a disease. Incorporating these three factors, we developed a predictive model for pT3a disease with predictive accuracy of area under the ROC curve of 0.772. Conclusions: Preoperative CRP is an independent predictor for pT3a disease in cT1 RCC along with age and tumor size. The model could be useful to estimate the risk of the probability of fat invasion before surgery, especially NSS. No significant financial relationships to disclose.
Collapse
|
25
|
Okada Y, Masuda H, Saito K, Iimura Y, Yokoyama M, Komai Y, Numao N, Koga F, Fujii Y, Kihara K. Surgical outcomes of gasless single port retroperitoneal radical nephrectomy for dialysis patients: A comparative analysis with nondialysis patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.376] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
376 Background: Gasless single port retroperitoneal radical nephrectomy is minimally invasive, curative and cost effective operation which we have developed since 1998 (Eur Urol Suppl 2009; 8: 392), and covered by the Japanese universal insurance system from April, 2008. Patients necessitating dialysis are considered high risk operative candidates because of their multiple comorbidities. We compared surgical outcomes of dialysis patients with non-dialysis patients to evaluate this operation as treatment for high risk group. Methods: We reviewed 304 consecutive patients including 59 (19.4%) dialysis patients who underwent CO2 gasless single port retroperitoneal radical nephrectomy at our institute between 2000 and 2009. Complications within the first 30 days after the surgery were graded retrospectively according to the modified Clavien classification system. Patient demographics, operative outcomes, and complications were compared between dialysis and non-dialysis patients. Results: In all patients, the median patient age and body mass index were 60 years and 23.0 kg/m2. The median length of surgical incision, operative time (OT) and estimated blood loss (EBL) were 6.5 cm, 189 minutes and 214 mL, respectively. The transfusion rate was 3.3%. The intra and postoperative complication rate were 3.9% and 10.1%. Two grade 3a (ureteral obstruction, 1; diverticulitis, 1), three grade 3b (occlusion of peripheral hemodialysis shunt, 3) and two grade 4 (pulmonary embolism, 1; acute heart failure, 1) surgical complications occurred. In dialysis patients, the mean BMI was lower (20.4 vs. 23.3, p<0.0001), the mean OT was shorter (170 vs. 201 minutes, p<0.0001) and the mean EBL was lower (216 vs. 311mL, p<0.0001) than non-dialysis patients. There was no Clavien grade 3 or 4 surgical complications except dialysis access occlusion in dialysis patients. The average time to oral feeding and walking were equivalent, but possible discharge were longer in dialysis patients (4.3 vs. 3.4 days, p<0.0037). Conclusions: Our data supports the safety and feasibility of gasless single port retroperitoneal radical nephrectomy for dialysis patients. No significant financial relationships to disclose.
Collapse
|